HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
Asia Biotech Live
LATEST UPDATES » Vol 24, No 01, January 2020 – Empowering the Patient - Personalization of Diabetes Management       » First of its kind Human Heart-in-a-Jar Model for therapeutic solutions       » China's National Vaccine Tracking System set to be completed in 2020       » China's amended drug administration law kicks in       » Human activity puts Chinese plant biodiversity at risk, study finds       » Contributory effects of each brain cell type in development of Alzheimer's Disease      
Vol 23, No. 11, November 2019For e-subscribers (PDF)
INSIDE INDUSTRY
Boston-based Singapore start-up gains FDA approval for AI-powered analytics engine for physiological monitoring
Biofourmis received approval from the U.S. Food and Drug Administration (FDA) for its Biovitals™ Analytics Engine in May 2019.

Digital therapeutics company, Biofourmis, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its machine-learning and artificial intelligence (AI)-powered Biovitals™ Analytics Engine as a medical device for ambulatory physiological monitoring.

This regulatory approval of the Biovitals™ Analytics Engine is part of FDA’s growing recognition of machine-learning and AI in the Software as a Medical Device category.

“This milestone approval is foundational to the Biovitals™ ecosystem, which includes not only our most advanced solution, BiovitalsHF™ for heart failure—but also our range of solutions across therapeutic areas, such as pain, oncology, sleep disorders and others in development,” said Kuldeep Singh Rajput, CEO and founder of Biofourmis. “Receiving this important regulatory approval will only accelerate the development and commercialization of these innovative digital therapeutic solutions.”

This FDA approval is the second market authorization for Biofourmis, having earned the agency’s approval in May 2019 for its Biovitals™ RhythmAnalytics™ platform, a cloud-based software for automated interpretation of over 15 types of cardiac arrhythmias. The newly cleared Analytics Engine is a much broader approval to process multiple physiology signals, as the technology serves as the foundation for all of Biofourmis’ digital therapeutics product pipeline.

The Biovitals™ Analytics Engine receives physiologic data in near real-time from FDA-cleared sensors and leverages AI and machine learning to identify the correlation between multiple vital signs and the patient’s daily activities. The Biovitals™ Analytics Engine computes a time series Biovitals™ Index, which reflects and alerts providers to changes in patients measured vital signs from their baseline.This advance notice provides ample time for the clinician to take the necessary clinical steps to change the trajectory of the disease.

In addition to benefitting patients, the Biovitals™ platform can potentially reduce hospital readmissions and decreases the need for emergency department (ED) visits.

“As the healthcare industry transitions to risk-bearing, value-based care models, tools such as the Biovitals™ Analytics Engine are essential to efficiently and effectively monitor and detect changes in patients’ health status before an adverse event leads to an ED visit or a hospital readmission,” said Maulik Majmudar, MD, a cardiologist and Biofourmis Clinical Advisory Board member.

Click here for the complete issue.

NEWS CRUNCH  
news Joining Forces to Elevate Asia's Healthcare Industry
news 4th Global Feed Summit draws Feed Producers, Technology Providers, Raw Materials Suppliers to Bangkok for Key Discussions
news 2nd China Pharma Digital Innovation Summit to be held in Shanghai
news 2nd China Healthcare Digital Innovation Summit to be held in Shanghai
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2020 World Scientific Publishing Co Pte Ltd  •  Privacy Policy